Nanotherapeutics in the EU: an overview on current state and future directions

Anita Hafner,1,* Jasmina Lovrić,1,* Gorana Perina Lako&scaron;,2 Ivan Pepić1,3 1Department of Pharmaceutical Technology, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, Croatia; 2Medicines Authorisation Division, Agency for Medicinal Products and Medical Devices, Zagreb, Cro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hafner A, Lovrić J, Perina Lako&scaron; G, Pepić I
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ed0a191d1f504080b679d7a770d0d356
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ed0a191d1f504080b679d7a770d0d356
record_format	dspace
spelling	oai:doaj.org-article:ed0a191d1f504080b679d7a770d0d3562021-12-02T02:10:29ZNanotherapeutics in the EU: an overview on current state and future directions1178-2013https://doaj.org/article/ed0a191d1f504080b679d7a770d0d3562014-02-01T00:00:00Zhttp://www.dovepress.com/nanotherapeutics-in-the-eu-an-overview-on-current-state-and-future-dir-a15874https://doaj.org/toc/1178-2013 Anita Hafner,1,* Jasmina Lovrić,1,* Gorana Perina Lako&scaron;,2 Ivan Pepić1,3 1Department of Pharmaceutical Technology, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, Croatia; 2Medicines Authorisation Division, Agency for Medicinal Products and Medical Devices, Zagreb, Croatia; 3Centre for Applied Pharmacy, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, Croatia *These authors contributed equally to this work Abstract: The application of nanotechnology in areas of drug delivery and therapy (ie, nanotherapeutics) is envisioned to have a great impact on public health. The ability of nanotherapeutics to provide targeted drug delivery, improve drug solubility, extend drug half-life, improve a drug’s therapeutic index, and reduce a drug’s immunogenicity has resulted in the potential to revolutionize the treatment of many diseases. In this paper, we review the liposome-, nanocrystal-, virosome-, polymer therapeutic-, nanoemulsion-, and nanoparticle-based approaches to nanotherapeutics, which represent the most successful and commercialized categories within the field of nanomedicine. We discuss the regulatory pathway and initiatives endeavoring to ensure the safe and timely clinical translation of emerging nanotherapeutics and realization of health care benefits. Emerging trends are expected to confirm that this nano-concept can exert a macro-impact on patient benefits, treatment options, and the EU economy. Keywords: nanotechnology, drug delivery, EU approval procedures, EU marketed productsHafner ALovrić JPerina Lako&scaron; GPepić IDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2014, Iss Issue 1, Pp 1005-1023 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Hafner A Lovrić J Perina Lako&scaron; G Pepić I Nanotherapeutics in the EU: an overview on current state and future directions
description	Anita Hafner,1,* Jasmina Lovrić,1,* Gorana Perina Lako&scaron;,2 Ivan Pepić1,3 1Department of Pharmaceutical Technology, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, Croatia; 2Medicines Authorisation Division, Agency for Medicinal Products and Medical Devices, Zagreb, Croatia; 3Centre for Applied Pharmacy, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, Croatia *These authors contributed equally to this work Abstract: The application of nanotechnology in areas of drug delivery and therapy (ie, nanotherapeutics) is envisioned to have a great impact on public health. The ability of nanotherapeutics to provide targeted drug delivery, improve drug solubility, extend drug half-life, improve a drug’s therapeutic index, and reduce a drug’s immunogenicity has resulted in the potential to revolutionize the treatment of many diseases. In this paper, we review the liposome-, nanocrystal-, virosome-, polymer therapeutic-, nanoemulsion-, and nanoparticle-based approaches to nanotherapeutics, which represent the most successful and commercialized categories within the field of nanomedicine. We discuss the regulatory pathway and initiatives endeavoring to ensure the safe and timely clinical translation of emerging nanotherapeutics and realization of health care benefits. Emerging trends are expected to confirm that this nano-concept can exert a macro-impact on patient benefits, treatment options, and the EU economy. Keywords: nanotechnology, drug delivery, EU approval procedures, EU marketed products
format	article
author	Hafner A Lovrić J Perina Lako&scaron; G Pepić I
author_facet	Hafner A Lovrić J Perina Lako&scaron; G Pepić I
author_sort	Hafner A
title	Nanotherapeutics in the EU: an overview on current state and future directions
title_short	Nanotherapeutics in the EU: an overview on current state and future directions
title_full	Nanotherapeutics in the EU: an overview on current state and future directions
title_fullStr	Nanotherapeutics in the EU: an overview on current state and future directions
title_full_unstemmed	Nanotherapeutics in the EU: an overview on current state and future directions
title_sort	nanotherapeutics in the eu: an overview on current state and future directions
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/ed0a191d1f504080b679d7a770d0d356
work_keys_str_mv	AT hafnera nanotherapeuticsintheeuanoverviewoncurrentstateandfuturedirections AT lovricj nanotherapeuticsintheeuanoverviewoncurrentstateandfuturedirections AT perinalakoscarong nanotherapeuticsintheeuanoverviewoncurrentstateandfuturedirections AT pepici nanotherapeuticsintheeuanoverviewoncurrentstateandfuturedirections
_version_	1718402685375348736

Nanotherapeutics in the EU: an overview on current state and future directions

Ejemplares similares